# A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

> **NCT02487316** · PHASE4 · WITHDRAWN · sponsor: **Jun Zhu**

## Conditions studied

- Systemic Anaplastic Large-Cell Lymphoma

## Interventions

- **DRUG:** crizotinib

## Key facts

- **NCT ID:** NCT02487316
- **Lead sponsor:** Jun Zhu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2017-11
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-12-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02487316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02487316, "A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02487316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*